Aleksey Krylov is a serial entrepreneur and seasoned Chief Financial Officer (CFO) for high-growth businesses. With a venture investing and investment banking background, his track record includes over 70 fundraising, going-public, and M&A transactions. Aleksey is a natural leader with experience in managing teams and daily operations for high-growth organizations. 

​

Previously, Aleksey served as the CFO for CytoImmune Therapeutics for three years. He led the finance function within the organization during that transformative period, helped secure over $100 million in funding and managed the expansion of the workforce from five to over 60 employees. Furthermore, he played a pivotal role in building a cutting-edge commercial-scale cell and biologics manufacturing facility.

​

Previously, as CFO of DIH International, Aleksey led the NASDAQ IPO prep for the Swiss-Chinese medical equipment manufacturer, driving strategic initiatives to optimize growth and maximize shareholder value.

​

As CFO of SELLAS Life Sciences, he orchestrated a successful reverse merger of the company into a public company and secured SELLAS’ listing on NASDAQ. He also led a successful convertible PIPE fundraise.

​

Before his stints as a healthcare CFO, Aleksey spent 12 years as a family office investment professional. He oversaw principal minority and control investments exceeding $500 million across diverse industries, including life sciences, medical technologies, healthcare IT, and consumer products. He started his career as an equity capital markets banker with Cowen’s investment banking practice.

​

Aleksey holds an MBA from Columbia Business School and a Bachelor of Science in Business Administration from Babson College.

​

His ability to blend financial acumen, deal-making expertise, and operational leadership makes him an invaluable asset to life sciences and medical technology organizations, driving transformative growth and financial performance.